论文部分内容阅读
106名2型糖尿病患者,随机、对称分为治疗组(格列美脲+二甲双胍)和对照组(格列吡嗪+二甲双胍)为期6月治疗,观察BMI、FPG 2、hPG、HbA1c、FINS、HOMA-IR变化及低血糖发生率。结果两组BMI、FPG、2hPG、HbA1c治疗后较治疗前差异性明显(P<0.05),组间无差异(P>0.05);治疗组FINS、HOMA-IR较对照组低(P<0.05);治疗组低血糖发生率低(P<0.01)。结论格列美脲较格列吡嗪,节约内源性胰岛素,改善胰岛素抵抗,低血糖发生率低。
106 patients with type 2 diabetes were randomly divided into treatment group (glimepiride + metformin) and control group (glipizide + metformin) for 6 months. BMI, FPG 2, hPG, HbA1c, FINS, HOMA-IR changes and the incidence of hypoglycemia. Results The differences of BMI, FPG, 2hPG and HbA1c between the two groups after treatment were statistically significant (P <0.05), but there was no significant difference between the two groups (P> 0.05). The FINS and HOMA-IR of the treatment group were lower than those of the control group The incidence of hypoglycemia in the treatment group was lower (P <0.01). Conclusion Glimeporide is better than glipizide, which can save endogenous insulin, improve insulin resistance and lower the incidence of hypoglycemia.